HealthcareInvestment

Patterson Companies to be Acquired by Patient Square Capital in Strategic Deal

12 days ago

Patterson Companies, a prominent name in the dental and veterinary supply sectors, has reached an agreement to be acquired by Patient Square Capital. This investment firm is set to pay between $31.35 and $34.50 per share in a bid to take Patterson private. The offer values the company at approximately $1.5 billion, signaling a significant investment in the healthcare industry, particularly in the dental and animal health spaces.

Valeas Capital Partners Secures $600 Million for Groundbreaking Inaugural Fund

18 days ago

In a significant move within the private equity sector, Valeas Capital Partners has announced the successful closing of its inaugural fund, raising an impressive $600 million. This milestone not only underscores investor confidence in Valeas but also positions the firm firmly within an increasingly competitive landscape.

Major Capital Injection Expected for HIG's Kora Saúde: What It Means for the Future

27 days ago

In an important development within the healthcare sector, creditors are reportedly organizing a substantial capital infusion for Kora Saúde, a company backed by HIG Capital. This capital boost is seen as crucial for maintaining the operations of Kora Saúde, which has faced financial challenges in recent times. Such a move signals confidence from creditors in the company's potential for recovery and growth.

Indivior Secures Financial Stability with Debt Refinancing Deal

2 months ago

Indivior, the global pharmaceutical company known for its treatments for addiction and mental health disorders, has successfully extended the maturity of its debt through a strategic refinancing of its term loan. This maneuver is aimed at enhancing the company's financial flexibility and overall stability as it navigates the post-pandemic recovery landscape.

CD&R Takes Strategic Steps to Alleviate French Concerns Over Sanofi Acquisition

2 months ago

In a proactive effort to address rising concerns from the French government regarding its acquisition of Sanofi, private equity firm Clayton, Dubilier & Rice (CD&R) is reportedly preparing to implement measures aimed at easing these apprehensions. The initiatives come as the proposed purchase of the French pharmaceutical giant by CD&R has stirred significant trepidation among stakeholders in France, particularly in light of the country's focus on safeguarding its strategic industries.